TopGene

About TopGene

Founded in November 2014, TopGene, also known as Top Medical Tech, is a Guangzhou-based biotechnology firm focused on the development of non-invasive cancer diagnostics. The company's core mission is to provide personalized and more effective healthcare by analyzing the unique genetic composition of each patient's tumor. This approach allows for a deeper understanding of the genomic alterations that drive tumor growth and their response to various treatments.

TopGene's primary service revolves around DNA testing and precision medicine, with a specific focus on screening for genes associated with breast, colorectal, and lung cancers. The process involves using blood or tissue samples for diagnosis. The platform then employs quantitative polymerase chain reaction (qPCR) to detect mutations and monitor the genomic changes that influence tumors. By amplifying and sequencing these mutations, TopGene can identify specific somatic mutations. This data is then utilized for comprehensive genetic mutation analysis and aids in selecting appropriate drugs, culminating in a precision medicine report for clinicians. This enables healthcare providers to make more informed decisions, aiming for better patient outcomes.

The company operates in the biotechnology and life sciences sectors, specifically within the oncology and laboratory services industries. Its clients are primarily clinicians and healthcare providers who utilize the diagnostic services to guide cancer treatment strategies. As a privately held, venture capital-backed entity, TopGene has secured significant financial support to advance its operations. A key funding event was a Series A round on August 3, 2018, which raised $14.6 million, with Guangzhou Yuexiu Industrial Investment Fund Management as a lead investor. In total, the company has raised approximately $29.2 million to support its growth and research endeavors.